Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENIGMA
2023-508335-31-00Phase 4Authorised
- Sponsor
- UCLouvain
- Start
- Mar 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus and mycophenolate mofetil in chronic kidney disease (CKD) and Kidney allograft status (RTx), sponsored by UCLouvain. Planned start Mar 2024; status: authorised.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
chronic kidney disease (CKD)Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2023-508335-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508335-31-00.